[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100275728":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":18,"centralContacts":40,"locations":44,"responsibleParty":132,"collaborators":135,"id":144,"slug":145,"hasResults":146,"nctId":147,"briefTitle":148,"officialTitle":148,"acronym":10,"eligibilityCriteria":149,"healthyVolunteers":150,"sex":151,"minAge":152,"maxAge":10,"enrollmentInfo":153,"targetDuration":10,"studyType":156,"phases":10,"briefSummary":157,"conditions":158,"keywords":162,"overallStatus":47,"whyStopped":10,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":179},{"fullName":5,"class":6},"Rigshospitalet, Denmark","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"ALS patients",null,"Patients diagnosed with ALS will be included in this group. Blood and spinal fluid samples will be stored in biobank and later analyzed. A subset of this group (20 ALS patients) will give blood and spinal fluid every 6 months during progression of the disease. A subset of 10 will donate a muscle biopsy.",{"label":13,"type":10,"description":14,"interventionNames":10},"Control group with patients with other neurological disease","Patients referred to hospital with symptoms of acute or chronic headache.",{"label":16,"type":10,"description":17,"interventionNames":10},"Neurologically healthy control group","Patients having orthopaedic surgery performed in spinal anaesthesia.",[19,23,26,29,32,34,37],{"name":20,"affiliation":21,"role":22},"Kirsten Møller, Prof., MD","Clinic of Neuroanestesiology, Rigshospitalet, Denmark","STUDY_CHAIR",{"name":24,"affiliation":25,"role":22},"Peter Garred, Prof., MD","Department of Clinical Immunology",{"name":27,"affiliation":28,"role":22},"Stephen Wørlich Pedersen, dr.med","Dept. of Neurology, Rigshospitalet Glostrup",{"name":30,"affiliation":31,"role":22},"Karsten Skovgaard Olsen, Dr.med.","Clinic of Neuroanaestesiology, Rigshospitalet Glostrup",{"name":33,"affiliation":31,"role":22},"Anne Øberg Lauritsen, MD",{"name":35,"affiliation":36,"role":22},"Eva Løbner Lund, MD, PhD","Dept. of Pathology, Rigshospitalet",{"name":38,"affiliation":31,"role":39},"Anne-Lene Kjældgaard, MD","PRINCIPAL_INVESTIGATOR",[41],{"name":38,"role":42,"phone":10,"phoneExt":10,"email":43},"CONTACT","akja004@regionh.dk",[45,61,71,82,89,97,108,120],{"facility":46,"status":47,"city":48,"state":10,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Dept. of Neurology Aarhus Hospital, Nørrebrogade","RECRUITING","Aarhus","8000","Denmark","DK",{"type":53,"coordinates":54},"Point",[55,56],10.21076,56.15674,{"lat":56,"lon":55},[59],{"name":60,"role":42,"phone":10,"phoneExt":10,"email":10},"Anette Torvin Møller, MD, PhD",{"facility":62,"status":63,"city":64,"state":10,"zip":65,"country":50,"countryCode":51,"cosmosGeoPoint":66,"geoPoint":70,"contacts":10},"Gildhøj Private Hospital","COMPLETED","Brøndby","2605",{"type":53,"coordinates":67},[68,69],12.41008,55.6455,{"lat":69,"lon":68},{"facility":72,"status":47,"city":73,"state":10,"zip":74,"country":50,"countryCode":51,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Clinic of neuroanestesiology, Rigshospitalet Glostrup","Copenhagen","2600",{"type":53,"coordinates":76},[77,78],12.56553,55.67594,{"lat":78,"lon":77},[81],{"name":38,"role":42,"phone":10,"phoneExt":10,"email":10},{"facility":83,"status":47,"city":84,"state":10,"zip":85,"country":50,"countryCode":51,"cosmosGeoPoint":10,"geoPoint":10,"contacts":86},"Dept. of Neurology, Bisbebjerg Hospital","Copenhagen NV","2400",[87],{"name":88,"role":42,"phone":10,"phoneExt":10,"email":10},"Merete Karlsborg, MD",{"facility":90,"status":91,"city":92,"state":10,"zip":93,"country":50,"countryCode":51,"cosmosGeoPoint":10,"geoPoint":10,"contacts":94},"Clinic of Neurosurgery, Rigshospitalet","NOT_YET_RECRUITING","Copenhagen Ø","2100",[95],{"name":96,"role":42,"phone":10,"phoneExt":10,"email":10},"Marianne Juhler, dr.med, prof",{"facility":98,"status":47,"city":99,"state":10,"zip":74,"country":50,"countryCode":51,"cosmosGeoPoint":100,"geoPoint":104,"contacts":105},"The Dept. og Neurology, Rigshospitalet Glostrup","Glostrup Municipality",{"type":53,"coordinates":101},[102,103],12.40377,55.6666,{"lat":103,"lon":102},[106],{"name":107,"role":42,"phone":10,"phoneExt":10,"email":10},"Elisabeth Elmo, MD",{"facility":109,"status":47,"city":110,"state":10,"zip":111,"country":50,"countryCode":51,"cosmosGeoPoint":112,"geoPoint":116,"contacts":117},"Dept. of Neurology, Odense Hospital","Odense C","5000",{"type":53,"coordinates":113},[114,115],10.39538,55.40841,{"lat":115,"lon":114},[118],{"name":119,"role":42,"phone":10,"phoneExt":10,"email":10},"Matthias Bode, MD",{"facility":121,"status":47,"city":122,"state":10,"zip":123,"country":50,"countryCode":51,"cosmosGeoPoint":124,"geoPoint":128,"contacts":129},"The dept. of Neurology, Roskilde Hospital","Roskilde","4000",{"type":53,"coordinates":125},[126,127],12.08035,55.64152,{"lat":127,"lon":126},[130],{"name":131,"role":42,"phone":10,"phoneExt":10,"email":10},"Helle Thagesen, MD",{"type":39,"investigatorFullName":133,"investigatorTitle":134,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Anne-Lene Kjældgaard","Ph.d.-student, MD",[136,138,140,142],{"name":137,"class":6},"Zealand University Hospital",{"name":139,"class":6},"Bispebjerg Hospital",{"name":141,"class":6},"Aarhus University Hospital",{"name":143,"class":6},"Odense University Hospital","100275728","amyotrophic-lateral-sclerosis-and-the-innate-immune-system-100275728",false,"NCT02869048","Amyotrophic Lateral Sclerosis and the Innate Immune System","Inclusion Criteria:\n\n* For ALS group:Diagnosed with the diagnose category \"certain ALS\" or \"likely ALS according to the El Escorial rev. diagnose criteria\n* For Neurological control group: Referred to neurological department to be examined for acute or chronic headache or referred to get a lumbar perfusion test performed.\n\nExclusion Criteria:\n\n* For all groups (Clinical study 2-3): permanent contraindication for having a lumbar puncture performed\n* For Neurological control group: Known with chronic inflammatory disease or autoimmune disease.\n* For healthy control group (clinical study 1): Known with any disease\n* For healthy control group (clinical study 1): Taking daily medication\n* For Neurologically healthy control group (Clinical study 2): Known with neurological disease\n* For Neurologically healthy control group (Clinical study 2): Known with chronic inflammatory disease or autoimmune disease.",true,"ALL","18 Years",{"count":154,"type":155},375,"ESTIMATED","OBSERVATIONAL","Amyotrophic Lateral Sclerosis (ALS) is an aggressive, deadly disease. ALS leads to destruction of the neural pathways which control the conscious movements of the muscles. This destruction leads to muscular dystrophy with increasing difficulties in moving, breathing, swallowing, and speaking. In the last phase of an ALS patient's life it is necessary with respiratory therapy in order to breathe. In average an ALS patient lives 3 years from the time he or she gets the diagnose.\n\nThe cause of the disease is still unknown and there is currently no treatment which can stop the progression of the disease. Former clinical studies have indicated that the innate immune system and in particular the complement system plays a significant role in the progression of ALS. The complement system, which is activated in cascades, is part of the innate system but participates in the innate as well as the acquired immune system. Former clinical trials have been characterized by limited knowledge about both the complement system as well as to how it is measured.\n\nToday it is possible to measure directly on the different components of the complement system and to understand its contribution to the overall immune response. It is also possible today to detect defects of the complement system. All these progressions are the foundation for this project which is carried out in close cooperation with one of the world's leading researchers in the complement system, professor Peter Garred from Rigshospitalet.\n\nThe aim is to make a national research project about ALS in order to investigate the role of the innate immune system, and especially the complement system, in patients with ALS.\n\nIn the long term the hope is, that this will lead the way to a targeted and effective medical treatment to the people affected by this grave disease.",[159,160,161],"Amyotrophic Lateral Sclerosis","Neurodegenerative Disease","Motor Neuron Disease",[163,164,165,166,167,168,169],"Biological Specimen Banks","Innate Immunity","Clinical Study","Complement system proteins","Amyotrophic lateral sclerosis","Neurodegenerative disease","Motor neuron disease","2017-10-04",{"date":172,"type":173},"2017-10-06","ACTUAL",{"date":175,"type":10},"2016-06",{"date":177,"type":155},"2026-06",{"name":5,"class":6},8]